(Q41729322)

8 October 2017

1 reference

title

Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies (English)

1 reference

8 October 2017

1 reference

Epstein JB

1

1 reference

8 October 2017

Polsky B

series ordinal

2

1 reference

8 October 2017

language of work or name

1 reference

1 January 1998

1 reference

8 October 2017

published in

Clinical Therapeutics

1 reference

8 October 2017

volume

20

1 reference

8 October 2017

issue

1

1 reference

8 October 2017

page(s)

40-57

1 reference

Antifungal therapy in oropharyngeal mycotic infections

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Treatment of oropharyngeal candidiasis in HIV-positive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Oral and pharyngeal candidiasis. Topical agents for management and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Candida laryngotracheitis: a complication of combined steroid and antibiotic usage in croup

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Treatment of Oral Candida Mucositis Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Candida in patients with oral lichen planus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apo-lactoferrin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Oral and gastrointestinal candidosis: prophylaxis during immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Acute oral candidiasis during febrile episodes in immunocompromised patients with haematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

The pathogenesis and clinical significance of cytologically detectable oral Candida in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Fluconazole-resistant Candida in AIDS patients. Report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

1 reference

7 January 2021

Oral and dermatologic manifestations of HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Diagnosis and treatment of oral candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Comparative trial of fluconazole and amphotericin in the treatment of denture stomatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Oral candidiasis: pathogenesis and host defense

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Detection of amphotericin B-resistant Candida isolates in a broth-based system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Antifungal susceptibility tests

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Effect of nystatin and chlorhexidine digluconate on Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Clotrimazole treatment of oral candidiasis in patients with neoplastic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Overview of studies of fluconazole in oropharyngeal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Disseminated Candidiasis Due to Amphotericin B-Resistant Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Oral candidiasis and human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Fungemia due to fluconazole-resistant Candida albicans in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Treatment of refractory oral candidiasis with fluconazole. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Development of resistance in candida isolates from patients receiving prolonged antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Salivary concentrations of amphotericin B following its use as an oral lozenge

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

Antifungal agents used for deep-seated mycotic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980033-7

7 January 2021

10.1016/S0149-2918(98)80033-7

Identifiers

DOI

1 reference

8 October 2017

1 reference